Triethylenetetramine

Generic Name
Triethylenetetramine
Brand Names
Cuvrior, Syprine, Cuprior, Cufence
Drug Type
Small Molecule
Chemical Formula
C6H18N4
CAS Number
112-24-3
Unique Ingredient Identifier
SJ76Y07H5F
Background

Triethylenetatramine (TETA), also known as trientine, is a potent and selective copper (II)-selective chelator. It is a structural analog of linear polyamine compounds, spermidine and spermine. TETA was first developed in Germany in 1861 and its chelating properties were first recognized in 1925. Initially approved by the FDA in 1985 as a second-line treatment for Wilson's disease, TETA is currently indicated to treat adults with stable Wilson’s disease who are de-coppered and tolerant to penicillamine.

TETA has been investigated in clinical trials for the treatment of heart failure in patients with diabetes.

Indication

Triethylenetetramine is a copper chelator indicated for the treatment of adult patients with stable Wilson’s disease who are de-coppered and tolerant to penicillamine.

Associated Conditions
Wilson's Disease
Associated Therapies
-
Clinical Trials
Related News
m.thepeninsulaqatar.com
·

Promising drug for treating rare childhood cancer: Study

A UNSW study suggests adding TETA (Cuprior) to neuroblastoma treatment improves health by shrinking tumors and boosting immunity, potentially increasing survival rates from 10 to 50%. The drug transfers copper to immune cells, weakening tumors and enhancing immunotherapy response. It's non-toxic, cost-effective, and could improve quality of life for affected children.
qna.org.qa
·

Study: Promising Drug for Treating Rare Childhood Cancer

A study by UNSW suggests adding TETA (Cuprior) to treat neuroblastoma improves tumor shrinkage and immune response, potentially raising survival rates from 10 to 50%. The drug transfers copper to immune cells, weakening tumors and enhancing immunotherapy, with no toxic side effects.
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy